Brimonidine & Glaucoma Surgery Failure: New Risk Identified

A common medication used to manage glaucoma may significantly reduce the success rate of a surgical procedure designed to lower eye pressure, new research indicates. The study, published February 25, 2026, in the journal American Journal of Ophthalmology, found that preoperative use of brimonidine is associated with a nearly threefold increase in trabeculectomy failure due to high intraocular pressure (IOP). This finding adds a layer of complexity to glaucoma treatment planning and highlights the importance of a thorough medication review before surgery.

Understanding Trabeculectomy and Intraocular Pressure

Glaucoma, a leading cause of irreversible blindness worldwide, often involves elevated intraocular pressure – the fluid pressure inside the eye. While medications can often manage this pressure, sometimes surgery is necessary. Trabeculectomy is a surgical procedure that creates a new drainage pathway for the fluid in the eye, lowering IOP. Success is typically defined as achieving an IOP between 6 and 15 mmHg, or a greater than 20% reduction from baseline, without the demand for further surgery. Failure, means IOP remains too high, requiring additional intervention.

Brimonidine, a topical medication frequently prescribed for glaucoma, works by reducing the production of aqueous humor, the fluid within the eye, and by increasing its outflow. It’s generally well-tolerated, making it a popular choice for many patients. However, this new research suggests a potential trade-off when considering surgery.

Study Details and Findings

Researchers at a single academic center retrospectively analyzed data from 501 eyes of adult glaucoma patients who underwent primary trabeculectomy between January 1, 2015, and March 21, 2022. They examined electronic medical records, including demographics, diagnoses, IOP measurements, and medication histories. The study meticulously matched 43 unique formulations of glaucoma medications, accounting for different concentrations, brand names, and generic equivalents. Data accuracy was confirmed through manual chart review.

The results revealed a statistically significant association between preoperative brimonidine use and an increased risk of high IOP trabeculectomy failure (hazard ratio [HR] 2.87; p = 0.002). This means patients who used brimonidine before surgery were almost three times more likely to experience failure due to high IOP compared to those who did not. Higher baseline IOP also contributed to failure risk (HR 1.33; p = 0.014). Interestingly, other common glaucoma medications – beta blockers, prostaglandins, and carbonic anhydrase inhibitors – did not demonstrate a similar association with surgical failure. At three years post-surgery, the probability of success was 81.9% in the brimonidine group versus 93.36% in the non-brimonidine group (p < 0.00, log-rank test). Read the full study on PubMed.

What Does This Mean for Patients?

This study doesn’t mean patients should stop taking brimonidine. It does, however, suggest that ophthalmologists should carefully consider a patient’s medication history when planning a trabeculectomy. The findings underscore the need for a detailed discussion about the potential risks and benefits of continuing brimonidine use in the weeks leading up to surgery. It’s crucial to remember that correlation does not equal causation; this study demonstrates an association, but doesn’t definitively prove that brimonidine *causes* the increased failure rate. Other factors may be at play.

The researchers acknowledge that further investigation is needed to understand the underlying mechanisms driving this association. It’s possible that brimonidine alters the healing process after surgery, or affects the formation of scar tissue around the drainage site. Understanding these mechanisms is critical for developing strategies to mitigate the risk.

Limitations and Considerations

It’s important to note the limitations of this study. The retrospective observational design means that researchers observed existing data, rather than randomly assigning patients to different treatment groups. This introduces the potential for confounding factors – variables that could influence the results but weren’t directly measured or controlled. The study was also conducted at a single academic center, which may limit the generalizability of the findings to other populations or settings.

the study focused specifically on high IOP failure. It did not assess other potential causes of trabeculectomy failure, such as hypotony (low eye pressure) or bleb-related complications. The full text of the study in the American Journal of Ophthalmology provides a more detailed discussion of these limitations.

The Broader Context of Glaucoma Management

Glaucoma remains a significant public health challenge. The World Health Organization estimates that glaucoma is the second leading cause of blindness globally, affecting over 64 million people in 2020 and is projected to reach 76 million by 2030. WHO fact sheet on blindness. Effective management requires a multifaceted approach, including regular eye exams, medication adherence, and, in some cases, surgery.

The findings regarding brimonidine and trabeculectomy highlight the dynamic nature of medical knowledge and the importance of ongoing research. As new evidence emerges, treatment guidelines may evolve to optimize patient outcomes.

What Comes Next: Refining Surgical Approaches

The authors of this study suggest that further research is needed to explore the mechanisms underlying the association between brimonidine and trabeculectomy failure. Clinical trials could be designed to specifically investigate the impact of temporarily discontinuing brimonidine before surgery. Researchers could explore alternative surgical techniques or adjunctive therapies that might mitigate the risk of failure in patients who have previously used brimonidine. Ophthalmologists will likely be reviewing these findings and incorporating them into their clinical practice, emphasizing the importance of a comprehensive medication review and individualized treatment planning for glaucoma patients.